Risk Assessment Algorithms - Bleeding
Introduction
A number of risk assessment algorithms have been developed to predict the risk of bleeding in an individual with Atrial Fibrillation and in whom anticoagulation is planned. These are summarised below:
The ABH score is a clinical prediction rule for assessing the bleeding risk in patients with Atrial Fibrillation [AF] treated with a DOAC. In the initial score, 10 variables were analysed - see below. A simplified version of the score was subsequently developed using three variables: Age, a history of bleeding and non-bleeding related hospitalisation in the preceding 12 months - see ABH Score - Simplified.
Click HERE to access the ABH Score - Original and HERE to access the ABH Score - Simplified.
The ABS [Anticoagulation-specific Bleeding Score] Algorithm was developed to stratify the risk of bleeding in patients with Atrial Fibrillation on a DOAC [- Dabigatran, Rivaroxaban or Apixaban] or Warfarin. The model involves the use of 15 variables.
Click HERE for additional information on the ABS algorithm.
The ATRIA Bleeding Score score is a clinical prediction rule for estimating the risk of bleeding in a patient about to commence anticoagulation with warfarin.
Click HERE to access the ATRIA Bleeding algorithm.
The HAS-BLED Score is a clinical prediction rule for estimating the risk of major bleeding in patients with non-valvular Atrial Fibrillation [AF] on warfarin.
Click HERE to access the HAS-BLED Score.
The HEMORR2HAGES algorithm is a risk assessment model designed to quantify the risk of haemorrhage in patients with Atrial Fibrillation over the age of 75 years.
Click HERE to access the HEMORR2HAGES algorithm.
The ORBIT-AF Bleeding Score [Outcomes Registry for Better Informed Treatment of Atrial Fibrillation] is used to assess bleeding risk in patients with Atrial Fibrillation [AF on anticoagulation with oral anticoagulants. .
Click HERE to access the ORBIT-AF Score.
The ABC [Age/Biomarkers/Clinical History] Score is an algorithm for the prediction of major bleeding events that incorporates two clinical risk factors and three biomarkers.
Click HERE to access the ABC Score.
The SAMe-TT2R2 score was originally devised as a system for identifying individuals with Atrial Fibrillation in whom poor anticoagulation control was likely to be a problem. It was subsequently evaluated in patients with acute VTE to establish whether individuals with a SAMe-TT2R2 score that would predict poor anticoagulant control with a Vitamin K antagonist e.g. Warfarin would be more effectively treated with a DOAC.
Click HERE to access the SAMe-TT2R2 algorithm.